Endometrial cancer with tubal metastasis detected during laparoscopic surgery in a patient undergoing fertility-sparing treatment with medroxyprogesterone acetate: a case report and review of the literature

Objectives: Medroxyprogesterone acetate (MPA) therapy is useful as a fertility-sparing treatment for early endometrial cancer, but it poses a risk of progression and recurrence during the treatment. We report a case of endometrial cancer with tubal metastases after long-term MPA therapy and review the literatures focusing on the failure of fertility-sparing treatment. Case: A nulliparous, 40 years old woman was started on MPA therapy after being diagnosed with grade 1 endometrioid carcinoma confined to the endometrium. She achieved complete remission after 10 months of treatment, but no pregnancy was established by assisted reproductive technology (ART). Eleven months after the first MPA therapy ended, atypical endometrial hyperplasia was confirmed. The disease was in remission again after the second MPA therapy for 8 months. The patient did not become pregnant by subsequent ART. Finally, a total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed. The gross pathological specimen revealed a 13 mm mass near the left uterine cornu. Histopathology showed a left tube metastasis. She was diagnosed with FIGO stage IIIA endometrial cancer and underwent the staging surgery by laparotomy. After the second surgery, adjuvant chemotherapy was initiated. After 13 months of disease-free survival, a recurrence was histologically detected at the vaginal stump. Following intracavitary radiation therapy, there was no evidence of disease for 10 months. Conclusions: The patient undergoing fertility-sparing treatment should be apprised of a risk of life-threatening progression of the disease. Once the patient has opted out of fertility preservation, definitive hysterectomy should be strongly recommended.

Endometrial cancer; Fertility-sparing treatment; Laparoscopic surgery; Tubal metastasis; Vaginal stump recurrence

[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136: e359–e386.

[2] Saito T, Takahashi F, Katabuchi H, 2016 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the committee on gynecologic oncology. Japan Society of Obstetrics and Gynecology: patients annual report for 2014 and treatment annual report for 2009. Journal of Obstetrics and Gynaecology Research. 2017; 43: 1667–1677.

[3] Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975–2012. 2015. Available at: http://seer.cancer.gov/csr/1975_2012/ (Accessed: 9 September 2016).

[4] Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: a systematic review. Gynecologic Oncology. 2012; 125: 477–482.

[5] Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer diagnosis, treatment and follow-up. International Journal of Gynecological Cancer. 2016; 26: 2–30.

[6] Park JY, Nam JH. Progestin in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist. 2015; 20: 270–278.

[7] Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility- sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology. 2012; 207: 266.e1–266.e12.

[8] Qin Y, Yu Z, Yang J, Cao D, Yu M, Wang Y, et al. Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis. International Journal of Gynecological Cancer. 2016; 26: 1081–1091.

[9] Piretti M, congiu F, Ricciardi E, Maniglio P, Mais V, Angioni S. Conservative treatment of well-differentiated endometrial cancer: when and why it should be considered in young women. Ecancermedicalscience. 2019; 16; 13: 892.

[10] Park JY, Kim DY, Kim JH, Kim YM, KimKR, Kim YT, et al. Long- term outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). European Journal of Cancer. 2013; 49: 868–874.

[11] Wang Y, Yu M, Yang JX, Cao DY, Yuan Z, Zhou HM, et al. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15 years experience. International Journal of Clinical Oncology. 2019; 24: 712– 720.

[12] Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, et al. Treatment efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecologic Oncology. 2019; 153: 55–62.

[13] Giampaolino P, Sardo ADS, Mollo A, Rafffone A, Travaglino A, Boccelino A, et al. Hysteroscopic endometrial focal resection by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retorospective study. Journal of Minimally Invasive Gynecology. 2019; 26: 648–656.

[14] Mitsuhashi A, Habu Y, Kobayashi T, Kawarai Y, Ishikawa H, Usui H, et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. Journal of Gynecologic Oncology. 2019; 30: e90.

[15] Kaku T, Yoshicawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium young women: central pathologic review and treatment outcome. Cancer Letters. 2001; 167: 39–48.

[16] Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. MPA therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. European Journal of Gynaecological Oncology. 2001; 22: 217–220.

[17] Ota T, Yoshida M, Kiumra M, Kinoshita K. Clinicopathologic study of uterine endometrial caricinoma in young women aged 40 years and younger. International Journal of Gynecological Cancer. 2005; 15: 657–662.

[18] Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial caricinomas. BJOG: An International Journal of Obstetrics & Gynaecology. 2005; 112: 317–320.

[19] Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. Journal of Clinical Oncology. 2007; 25: 2798–2803.

[20] Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Human Reproduction. 2007; 22: 1953–1958.

[21] Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, et al. Combined phosphor-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage IA, G1 adenocarcinoma of the endometrium. Cancer Letters. 2007; 248: 112–122.

[22] Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia. Medicine. 2017; 96: e8034.

[23] Baker J, Obermair A, Gebski V, Jana M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecologic Oncology. 2012; 125: 263–270.

[24] Kim MK, Seong SJ, Kim YS, Song T, Kim M, Yoon BS, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. American Journal of Obstetrics and Gynecology. 2013; 209: 358.e1–358.e4.

[25] Cade TJ, Quinn MA, Rome RM, Neesham D. Long-term outcomes after progestogen treatment for early endometrial cancer. The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2013; 53: 566–570.

[26] Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG: An International Journal of Obstetrics and Gynaecology. 2010; 117: 879–884.

[27] Perri T, Korach J, Gotlieb WH, Beiner M, Meirow D, Friedman E, et al. Prolonged conservative treatment of endometrial cancer patients. International Journal of Gynecological Cancer. 2011; 21: 72–78.

[28] Angioni S, Loddo A, Milano F, Piras B, Minerba L, Melis GB. Detection of benign intracavity lesion in postmenoposal women with abnormal uterine bleeding: a prospective comparative study on outpatient hysteroscopy and blind biopsy. Journal of Minimally Invasive Gynecology. 2008; 15: 87–91.

[29] Mitsuhashi A, Shozu M. New therapeutic approaches for the fertility-sparing treatment of endometrial cancer. Journal of Obstetrics and Gynaecology Research. 2020; 46: 215–222.

[30] Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Annals of Oncology. 2016; 27: 262–266.

[31] Colombo N, Creutzberg C, Querleu D, Barahona M, Sessa C. Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers). Annals of Oncology. 2018; 28: iv153–iv156.

[32] Park J, Seong SJ, Kim T, Kim JW, Kim SM, Bae D, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstetrics and Gynecology. 2013; 121: 136–142.

[33] Chae SH, Shim SH, Lee SJ, Lee JY, Kim SN, Kang SB. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrial cancer. International Journal of Gynecological Cancer. 2019; 29: 77–85.

[34] Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawana K, Yano T, et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. International Journal of Gynecological Cancer. 2013; 23: 288–293.

[35] Yamagami W, Mikami M, Nagase S, Tabata T, Kobayashi Y, Kaneuchi M, et al. Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. Journal of Gynecological Oncology. 2018; 31: e18.

[36] Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, et al. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? Journal of Gynecologic Oncology. 2018; 29: e21.

[37] Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke WM, Ananth CV, et al. All-cause mortality in young women with endometrial cancer receiving progesterone therapy. American Journal of Obstetrics and Gynecology. 2017; 217: 669.e1–669.e13.

[38] Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987; 60: 2035–2041.

[39] Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, et al. Synchronous endometrial and ovarian carcinomas: evidence of clonality. Journal of the National Cancer Institute. 2016; 108: djv428.

[40] Schultheis AM, Ng CKY, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, et al. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. Journal of the National Cancer Institute. 2016; 108: djv427.

[41] Song T, Seong SJ, Bae D, Suh DH, Kim D, Lee K, et al. Synchronous primary cancers of the endometrium and ovary in young women: a Korean Gynecologic Oncology Group Study. Gynecologic Oncology. 2013; 131: 624–628.

[42] Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999; 212: 711–718.

[43] Leitao MM, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology. 2009; 113: 105–108.

[44] Chang YN, Zhang Y, Wang YJ, Wang LP, Duan H. Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertility and Sterility. 2011; 96: 957–961.